sibel berker karauzum

sibel berker karauzum


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
CACigdem Aydin
Cigdem Aydin
ZCZafer Cetin
Zafer Cetin
AMAyse Esra Manguoglu
Ayse Esra Manguoglu
FTFunda Tayfun
Funda Tayfun
OCOzden Altiok Clark
Ozden Altiok Clark
SKsibel berker karauzum
sibel berker karauzum

25 February 2022 in Gene
Verified
Journal Article
Closed access
YAYunus Arikan
Yunus Arikan
SKsibel berker karauzum
sibel berker karauzum
HUHilmi Uysal
Hilmi Uysal
EMErcan Mihci
Ercan Mihci
BNBanu Nur
Banu Nur
ATAsli Toylu
Asli Toylu

1 January 2019 in Cogent Medicine
Verified
Journal Article
Open access
CVCiftci Vildan
Ciftci Vildan
DSDarbas Sule
Darbas Sule
BTBilgen Turker
Bilgen Turker
HUHilmi Uysal
Hilmi Uysal
SKsibel berker karauzum
sibel berker karauzum
Amyotrophic lateral sclerosis is the most common motor neuron disease of the adulthood. Genetic analyses performed on cases with sporadic ALS (sALS) and familial ALS (fALS) have revealed mutations most commonly in the genes C9orf72, SOD1, TARDBP, FUS, and UBQLN2. The aim of this study was to investigate the presence and incidence of these most common genomic alterations in these genes of 30 ALS cases. Increase in the number of hexanucleotide repeats within the gene C9orf72 was investigated using the fragment analysis method. A heterozygote c.-45 + 162_-45 + 163insGGGGCC alteration was observed in the first intron of the C9orf72 gene in only two sALS cases (6.6%), c.72 + 133C>T alteration was observed in the first intron of the SOD1 gene in six fALS and two sALS cases (26.6%), a c.169 + 41C>A alteration was observed in the second intron of the same gene in one case, a c.239 + 34A>C alteration was observed in the third intron of the same gene in three fALS cases (10%), and a c.714 + 67_714 + 68insG alteration was observed in the fifth intron of the TARDBP gene in six sALS cases (20%). Three different genomic alterations were detected in the FUS gene; two silent variants p.G49G (c.147C>A) in 3 cases (10%) and p.Y97Y (c.291C>T) in 25 cases (83%) and an intronic variant c.1067-61T˃C in 4 cases (13%). A novel missense variant, p.G457H (c.1371G>C), was observed in the UBQLN2 gene in one case with sALS. Our study has revealed three novel and previously reported genomic alterations in the ALS-related genes.

1 January 2020 in Neurological Sciences and Neurophysiology
Verified
Journal Article
Closed access
CHCeren Hangül
Ceren Hangül
SBSelen Bozkurt
Selen Bozkurt
UBUğur Bilge
Uğur Bilge
SÖSebahat Özdem
Sebahat Özdem
HAHasan Altunbaş
Hasan Altunbaş
SKsibel berker karauzum
sibel berker karauzum
Background: Facioscapulohumeral muscular dystrophy (FSHD) occurs as a consequence of genetic deletion of D4Z4 repeats on chromosome 4q35. Onset of FSHD is earlier in males, suggesting that testosterone may trigger the disease. In accordance, the rapid progression of disease in women after menopause suggests a protective role for estrogen and progesterone. No studies have examined levels of all these hormones in relation with the severity of FSHD. Aims: To evaluate the possible correlation between the severity of FSHD with sex hormones, age, and genetic deletion on chromosome 4q35. Subjects and Methods: D4Z4 repeat units were investigated in 33 patients (19 males/14 females) with FSHD. In the blood samples, luteinizing hormone, follicle-stimulating hormone, free estriol, estradiol, free testosterone and total testosterone, progesterone, 17-OH progesterone, prolactin, albumin, and fibrinogen were measured. The severity of FSHD was identified using a Clinical Severity Score (CSS) scaling system. Spearman's correlation and regression analyses were performed as statistical analyses. Results: Age (P = 0.001, r = 0.541) and total testosterone (P = 0.045, r = 0.351) were positively correlated, and the progesterone/total testosterone (P = 0.025, r = −0.390) and estradiol/total testosterone ratios (P = 0.025, r = −0.389) were negatively correlated with the severity of FSHD. Conclusions: Our results indicate that age, total testosterone, ratios of estradiol and progesterone to total testosterone, but not deletion on chromosome 4q35, have a significant relation with the severity of FSHD. Given that both estrogen and testosterone treatment are considered in therapy, our results suggest that estrogen and progesterone but not testosterone are likely to be more effective on the severity of FSHD.

14 August 2020 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
CHceren hangül
ceren hangül
ECEsin Guvenir Celik
Esin Guvenir Celik
HKHacer Kaya
Hacer Kaya
OEOnur Eroglu
Onur Eroglu
HUHilmi Uysal
Hilmi Uysal
SKsibel berker karauzum
sibel berker karauzum
Objectives: There is a clinical variability and heterogeneity among Facioscapulohumeral Muscular Dystrophy (FSHD) patients. Escalation after menopause in women, early onset in men suggests that estrogen might be a protective factor on the course of FSHD. In spite of few molecular studies supporting the protective role of estrogen in FSHD in vitro , there is no study revealing the effect of estradiol on the protein levels of DUX4, β-catenin and PAX3/PAX7. In present study, we investigated the effect of estradiol treatment on the expressions of DUX4, β-catenin and PAX3/PAX7 protein levels. Materials and Methods: Primary myoblasts of 63 and 71 years old (63yM/71yM) males; 47 years old (47yF) female FSHD patients were used. Cells were processed under these conditions; (i) untreated, (ii) 10 nM-30 min estradiol and (iii) 10 nM-4 h estradiol treated. The expression of DUX4, PAX3/PAX7 and β-catenin were examined by western-blotting. Results: Expression of DUX4 significantly downregulated after 4 h treatment of estradiol while PAX3/PAX7 56 kDa variant expression upregulated in 71yM cells. β-catenin and PAX3 expression was variable among the samples. Conclusion: Our results suggest that estrogen might be a palliative treatment option via downregulation of DUX4 protein in DUX4 expressing FSHD patients.

25 October 2019 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
CACigdem Aydin
Cigdem Aydin
TUTurgay Ulas
Turgay Ulas
CHCeren Hangul
Ceren Hangul
OYOrhan Kemal Yucel
Orhan Kemal Yucel
UIUtku Iltar
Utku Iltar
SKsibel berker karauzum
sibel berker karauzum